Profound gastric mucosal changes and severe rebound acid hypersecretion after long‐term Vonoprazan use: A case report DOI Creative Commons
Hiroko Suda,

Shotaro Eto,

Koichi Sakurai

et al.

DEN Open, Journal Year: 2024, Volume and Issue: 5(1)

Published: Dec. 21, 2024

Abstract Vonoprazan is a novel acid blocker with greater potency than proton pump inhibitors. A Japanese study reported no significant safety concerns over 5 years of use; however, elevated serum gastrin and increased parietal cell foveolar hyperplasia were observed, long‐term data beyond are limited. We report case that used for 6 years, complicated by gastric epithelial changes during treatment acute duodenal mucosal lesions following its discontinuation. 76‐year‐old, treated inhibitors 10 was switched to due his worsening symptoms. After use, hemorrhagic hyperplastic polyps became prominent. Given about Vonoprazan's effect on the epithelium, medication changed high‐dose H2 therapy. Two months later, patient complained vomiting black tarry stools. Esophagogastroduodenoscopy revealed reduction but multiple erosions ulcers in duodenum. This indicates potent effects mucosa risk severe rebound hypersecretion after use.

Language: Английский

Proton Pump Inhibitor Use and Its Association With Asthma: A Systematic Review and Meta‐Analysis DOI Creative Commons
Ganesh Bushi, Mahalaqua Nazli Khatib, Suhas Ballal

et al.

Journal of Clinical Pharmacy and Therapeutics, Journal Year: 2025, Volume and Issue: 2025(1)

Published: Jan. 1, 2025

Background: Asthma is a prevalent chronic respiratory condition marked by airway inflammation and hyperresponsiveness, significantly impacting quality of life. Emerging evidence suggests potential association between proton pump inhibitor (PPI) use an increased risk asthma. This systematic review meta‐analysis assessed the relationship PPI development or exacerbation Methods: A search PubMed, Web Science, Embase databases was conducted, covering studies published from inception database to July 12, 2024. Observational examining asthma were included. Two reviewers independently extracted data using Nested Knowledge software, with study via Newcastle–Ottawa Scale. random‐effects performed, pooling odds ratios (ORs) hazard (HRs) assess association, heterogeneity evaluated I 2 statistic. Results: Fourteen studies, conducted 2009 2024 involving over 1.7 million participants, met inclusion criteria. The pooled HR showed 38% among users compared nonusers (HR, 1.38; 95% CI, 1.14–1.62). OR analysis indicated 29% higher (OR, 1.29; 1.23–1.35). had 81% histamine H receptor antagonist (H RA) 1.81; 1.09–2.53), patients PPIs 61% more likely experience exacerbations 1.61; 1.42–1.80). Conclusion: associated These findings underscore need for cautious prescribing further investigation into underlying mechanisms.

Language: Английский

Citations

0
Trends in Proton Pump Inhibitor Use in Sweden by Sex and Age: A Drug Utilisation Study DOI Creative Commons
Nele Brusselaers, Unnur Guðnadóttir, Lars Engstrand

et al.

Drug Safety, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 8, 2024

Language: Английский

Citations

3
Pharmacotherapeutic actions related to drug interaction alerts – a questionnaire study among Swedish hospital interns and residents in family medicine DOI Creative Commons
Carina Tukukino, Naldy Parodi López, Johan Lönnbro

et al.

European Journal of Clinical Pharmacology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 16, 2024

Abstract Purpose To explore how hospital interns and residents specialising in family medicine act on drug interaction alerts a specific patient case, general. Methods A 4-page questionnaire, including fictional case (73-year-old woman; 10 drugs the medication list triggering 11 alerts) questions regarding use of general, was distributed to during educational sessions (November‒December 2023). The respondents were instructed consider what actions they would take “a normal day at work” due risk interactions between patients’ drugs. In general questions, asked often access detailed information (from 1 = never 5 always) provided by knowledge resource, relation alert classification (D clinically significant, should be avoided; C can handled by, e.g., dose adjustment). Results questionnaire completed 55 69 (response rate: 98%). acted median 4 (range: 0‒8) drugs, most concerning repaglinide (in D with clopidogrel; 96% suggested action), omeprazole three citalopram, clopidogrel, levothyroxine, respectively; 71% 83% action). Among who answered about (rated 4/5) more interactions, 56 (59%) did so for versus 29 (31%) ( P < 0.001). Conclusion Physicians selectively, classifications seem guide are used.

Language: Английский

Citations

0
Profound gastric mucosal changes and severe rebound acid hypersecretion after long‐term Vonoprazan use: A case report DOI Creative Commons
Hiroko Suda,

Shotaro Eto,

Koichi Sakurai

et al.

DEN Open, Journal Year: 2024, Volume and Issue: 5(1)

Published: Dec. 21, 2024

Abstract Vonoprazan is a novel acid blocker with greater potency than proton pump inhibitors. A Japanese study reported no significant safety concerns over 5 years of use; however, elevated serum gastrin and increased parietal cell foveolar hyperplasia were observed, long‐term data beyond are limited. We report case that used for 6 years, complicated by gastric epithelial changes during treatment acute duodenal mucosal lesions following its discontinuation. 76‐year‐old, treated inhibitors 10 was switched to due his worsening symptoms. After use, hemorrhagic hyperplastic polyps became prominent. Given about Vonoprazan's effect on the epithelium, medication changed high‐dose H2 therapy. Two months later, patient complained vomiting black tarry stools. Esophagogastroduodenoscopy revealed reduction but multiple erosions ulcers in duodenum. This indicates potent effects mucosa risk severe rebound hypersecretion after use.

Language: Английский

Citations

0